Browse the corpus

Erythropoietin (EPO) is a glycoprotein hormone produced by the peritubular cells of the renal cortex. This hormone stimulates red blood cell production in response to low partial pressure of oxygen (pO2). Erythropoiesis-stimulating agents (ESAs), such as epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin β, are pharmacologically synthesized, recombinant forms of EPO. ESAs are indicated for conditions associated with impaired red blood cell production. This educational activity highlights the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of ESAs, comparing them to the physiology of natural erythropoietin. Additionally, this discussion covers the FDA-issued box warnings, administration, and toxicity of ESAs. Understanding the intricate pharmacology of ESAs allows healthcare professionals to tailor treatment plans to individual patient needs. This activity emphasizes the critical role of the interprofessional healthcare team and aims to equip healthcare professionals with essential knowledge and tools to advance patient outcomes and care standards. This knowledge facilitates informed decision-making in prescribing ESAs and optimizing dosage regimens while minimizing adverse reactions, ultimately enhancing patient care. Objectives: Evaluate the physiology of erythropoietin. Identify the indications for prescribing erythropoietin-stimulating agent therapy. Assess the contraindications and adverse events associated with erythropoiesis-stimulating agents. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from erythropoietin-stimulating agents. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Most EPO-stimulating agent toxicity cases are related to the adverse effects of chronic use. There are few case reports of acute toxicity. One involved a man who intentionally injected himself with recombinant human EPO, causing his hemoglobin to rise to a dangerously high level.[40] Cases of severe hypertension have been reported following ESA overdosage. Another study linked Environmental Protection Agency (EPA) water supply data with patient records from the United States Renal Data System (USRDS), revealing that even low levels of lead in community water systems are associated with decreased hemoglobin levels and increased use of ESAs in patients with end-stage kidney disease (ESKD).[41] Management of Overdose Patients should receive supportive care for hypertension, intravenous fluids, and serial phlebotomy. Severe cases may require erythrocytapheresis.[42]

Treating anemia in patients using ESAs requires an interprofessional team of medical providers. This team should include a nephrologist for patients with CKD, a hematologist/oncologist overseeing chemotherapy, appropriate nursing staff, a pharmacist for ESA dosing, and a phlebotomy or laboratory technician for blood sampling to monitor for improvement. The interprofessional team should arrange appropriate follow-up appointments to reassess the patient's health status and any adverse effects of the ESA; this is where specialty-trained nurses and pharmacists can play a significant role. Nurses have the most frequent contact with the patient while educating, monitoring for adverse effects, and administering the medication. Pharmacists with specialty oncology certification should monitor dosing, interactions, and lab values that may alter or stop the dosing of the ESA. Both nurses and pharmacists must chart and inform the treating physician of any findings, changes, or concerns. Patients should receive counseling on the potential adverse effects and when to seek immediate medical care. Emergency medical providers should be aware of the adverse effects of ESAs to risk-stratify patients for venous thromboembolism, acute coronary syndrome, ischemic stroke, and other emergent conditions related to ESA. Only through the coordinated effort of an interprofessional healthcare team can ESA therapy be administered safely and effectively, with minimal adverse events and optimal patient results.

Patients should receive counseling on the potential adverse effects and when to seek immediate medical care. Emergency medical providers should be aware of the adverse effects of ESAs to risk-stratify patients for venous thromboembolism, acute coronary syndrome, ischemic stroke, and other emergent conditions related to ESA. Only through the coordinated effort of an interprofessional healthcare team can ESA therapy be administered safely and effectively, with minimal adverse events and optimal patient results. Monitoring the hemoglobin level to optimize patient outcomes and minimize adverse effects is very important. A debate exists regarding the appropriate target hemoglobin in individuals treated with ESA. A pooled analysis of 9 randomized control trials on patients with CKD indicates that patients have higher mortality and morbidity from cardiovascular-related events when the patient's hemoglobin falls below 10 g/dL.[43] This pooled analysis showed no survival benefit for patients treated with ESA when the hemoglobin exceeded 13 g/dL. However, there was a higher incidence of adverse events such as hypertension, vascular access thrombosis, and stroke. Current guidelines advocate for tailoring target hemoglobin levels to individual needs. Optimal levels typically range between 11 and 12 g/dL, considering that higher doses of ESAs can increase the risk of thrombotic events. An interprofessional team approach and communication among clinicians (MDs, DOs, NPs, PAs), hematologists, pharmacists, and nurses are crucial to decreasing potential adverse effects and improving patient outcomes related to ESA.